The role of anticytokine therapy in heart failure: Recent lessons from preclinical and clinical trials?

Medical Clinics of North America

Volumn 87, Issue 2, 2003, Pages 419-440

  Feldman, Arthur M ^a   Kadokami, Toshiaki ^b   Higuichi, Yoshiro ^a   Ramani, Ravi ^b   McTiernan, Charles F ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CANDESARTAN; CYCLIC AMP; CYCLIC AMP DERIVATIVE; CYTOKINE ANTIBODY; ENALAPRIL; ETANERCEPT; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; ISOPRENALINE; OUABAIN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; SIMVASTATIN; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL RESEARCH; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE MODEL; DOWNSTREAM PROCESSING; HEART DILATATION; HEART FAILURE; HUMAN; INFLAMMATION; LONG TERM CARE; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY;

EID: 0037349548     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00189-X     Document Type: Review

References (106)

1. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-33.
2. Moss ML, Jin SL, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 1997;385:733-6.
3. Kriegier M, Perez C, DeFay K, et al, A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53:45-53.
4. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994;264:667-8.
5. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992;10:411-52.
6. Bachmaier K, Pummerer C. Kozieradzki I, et al. Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease. Circulation 1997;95:655-61.
7. Dembic Z, Loetscher H, Gubler U, et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990;2:231-7.
8. Brakebusch C, Nophar Y, Kemper O, et al. Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J 1992;11:943-50.
9. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990;265:1531-6.
10. Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989;42:270-5.
11. Vilcek J, Lee TH. Tumor necrosis factor. J Biol Chem 1991:266:7313-6.
12. Djeu JY, Blanchard DK, Richards AL, et al. Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. J Exp Med 1988;141:4047-52.
13. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986;163:1433-50.
14. Kwak EL, Larochelle DA, Beaumont C, et al. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis factor-alpha. J Biol Chem 1995;270:15285-93.
15. Larrick JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-α. FASEB J 1990;4:3215-23.
16. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
17. Old LJ. Tumor necrosis factor (TNF). Science 1985;230:630-2.
18. Tracey KJ, Vlassara H, Cerami A. Cachectin/tumour necrosis factor. Lancet 1989;1:1122-6.
19. Manicourt DH, Triki R, Fukuda K, et al. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993;36:490-9.
20. Kupferminc MJ, Peaceman AM, Wigton TR, et al. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. Am J Obstet Gynecol 1994;170:1752-7.
21. Harel Y, Silva M, Giroir B, et al. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest 1992;92:2110-6.
22. Wu CJ, Lovett M, Wong-Lee J, et al. Cytokine gene expression in rejecting cardiac allografts. Transplantation 1992;54:326-32.
23. Sandborn WJ. A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. Gastroenterology 1997;113:1042-3.
24. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
25. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-86.
26. MacGowan G, Mann DL, Kormos RL, et al. Circulating interleukin-6 in severe congestive heart failure. Am J Cardiol 1997;79:1128-31.
27. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
28. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
29. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-8.
30. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine data base from the Vesnarinone Trial (VEST). Circulation 2001;103:2055-9.
31. Dibbs Z, Thornby J, White BG, et al. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 1999:33:1935-42.
32. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11.
33. Rectenwald JE, Moldawer LL, Huber TS, et al. Direct evidence for cytokine involvement in neointimal hyperplasia. Circulation 2000;102:1697-702.
34. Ono K, Matsumori A, Shioi T, et al. Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. Circulation 1998;98:149-56.
35. Birks EJ, Burton PB, Owen V, et al. Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts. Circulation 2000;102:III352-III358.
36. Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000;102:2636-42.
37. Nagueh SF, Stetson SJ, Lakkis NM, et al. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 2001;103:1844-50.
38. Machado FS, Martins GA, Aliberti JC, et al. Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation 2000;102:3003-8.
39. Wada H, Saito K, Kanda T, et al. Tumor necrosis factor-alpha (TNF-alpha) plays a protective role in acute viralmyocarditis in mice: a study using mice lacking TNF-alpha. Circulation 2001;103:743-9.
40. Kurrelmeyer KM, Michael LH, Baumgarten G, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 2000;97:5456-61.
41. Kapadia S, Oral H, Lee J, et al. Hemodynamic regulation of tumor necrosis factor-α gene and protein expression in adult feline myocardium. Circ Res 1997;81:187-95.
42. Kalra D, Baumgarten G, Dibbs Z, et al. Nitric oxide provokes tumor necrosis factor-alpha expression in adult feline myocardium through a cGMP-dependent pathway. Circulation 2000;102:1302-7.
43. Murray DR, Prabhu SD, Chandrasekar B. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000;101:2338-41.
44. Prabhu SD, Chandrasekar B, Murray DR, et al. Beta-adrenergic blockade in developing, heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000;101:2103-9.
45. Takano H, Nagai T, Asakawa M, et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000;87:596-602.
46. Sadoshima J. Cytokine actions of angiotensin II. Circ Res 2000;86:1187-9.
47. Satoh M, Nakamura M, Satoh H, et al. Expression of tumor necrosis factor-alpha-converting enzyme and tumor necrosis factor-alpha in human myocarditis. J Am Coll Cardiol 2000;36:1288-94.
48. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
49. McTiernan CF, Lemster BH, Frye CS, et al. Interleukin-1beta inhibits phospholamban gene expression in cultured cardiomyocytes. Circ Res 1997;81:493-503.
50. Chung MK, Gulick TS, Rotondo RE, et al. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 1990;67:753-63.
51. Gulick T, Chung MK, Pieper SJ, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA 1989;86:6753-7.
52. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines antithetically alter expression of disintergrin-metalloprotease and tissue inhibitor of metalloproteinase-3 in neonatal rat cardiomyocytes [abstract]. J Am Coll Cardiol 1997;29(2):54A.
53. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 1999;42:162-72.
54. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92:2303-12.
55. Yokoyama T, Nakano M, Bednarczyk J, et al. Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1996;95:1247-52.
56. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382-91.
57. Kubota T, McTiernan CF, Frye CS, et al. Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J Card Fail 1997;3:117-24.
58. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 1997;81:627-35.
59. Li YY, Feng YQ, Kadokami T, et al. Modulation of matrix metalloproteinase activities remodels myocardial extracellular matrix in TNFα transgenic mice [abstract]. Circulation 1999;100:1-752.
60. Kubota T, Miyagishima M, Bounoutas GS, et al. Overexpression of tumor necrosis factor-a activates the expression of multiple members of the apoptosis pathway in transgenic mice [abstract]. Circulation 1998;98(17):I462.
61. Bounoutas GS, Kubota T, Miyagishima M, et al. Adenoviral-directed overexpression of soluble tumor necrosis factor receptors reverses myocarditis in transgenic mice with congestive heart failure [abstract]. Circulation 1998;98(17):I737.
62. Kubota T, Bounoutas GS, Miyagishima M, et al. Development of myocarditis in transgenic mice overexpressing tumor necrosis factor α is mediated in part by the selective induction of downstream proinflammatory cytokines and β-chemokines [abstract]. Circulation 1998;98:1345.
63. Li YY, Feng Q, Kadokami T, et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor-α can be modulated by anti-tumor necrosis factor-α therapy. Proc Natl Acad Sci USA 2000;97:12746-51.
64. Feldman AM, Li YY, McTiernan CF. Matrix metalloproteinases in pathophysiology and treatment of heart failure. Lancet 2001;357:654-5.
65. Siwik DA, Chang DL, Colucci WS. Interleukin-1 beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000;86:1259-65.
66. Li YY, Chen D, Watkins SC, et al. Mitochondrial abnormalities in tumor necrosis factor-alpha-induced heart failure are associated with impaired DNA repair activity. Circulation 2001;104:2492-7.
67. Kapadia S, Torre-Amione G, Yokoyama T, et al. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. Am J Physiol 1995;268:H517-H525.
68. Kolls J, Peppel K, Silva M, et al. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci USA 1994;91:215-9.
69. Kubota T, Bounoutas GS, Miyagishima M, et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000;101:2518-25.
70. Kadokami T, Frye C, Lemster B, et al. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 2001;104:1094-7.
71. Kadokami T, McTiernan CF, Kubota T, et al. Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am J Physiol Heart Circ Physiol 2001;280:H2281-H2291.
72. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure. Effects on left ventricular dimensions and function. Circ Res 1999;85:364-76.
73. Gunja-Smith Z, Morales AR, Romanelli R, et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross links. Am J Physiol 1996;148:1639-48.
74. Yoshimura T, Kurita C, Nagoa T, et al. Inhibition of tumor necrosis factor-alpha and interleukin-1 beta production by beta-adrenoceptor agonists from lipopolysaccha ride-stimulated human peripheral blood mononuclear cells. Pharmacology 1997;54:144-52.
75. Szabo C, Hasko G, Zingarelli B, et al. Isoproterenol regulates tumor necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology 1997;90:95-100.
76. Vanderpoll T, Coyle SM. Barbosa K, et al. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713-9.
77. Skudicky D, Bergemann A, Sliwa K, et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation 2001;103:1083-8.
78. Sliwa K, Skudicky D, Candy G, et al. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-3.
79. Zabel P, Wolter DT, Schonharting MM, et al. Oxpentifylline in endotoxaemia. Lancet 1989;23:1474-7.
80. Bergman MR, Holycross BJ. Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1996;279(1):247-54. [published erratum appears in J Pharmacol Exp Ther 1997;280(1):520].
81. Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001;37:412-7.
82. Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714-21.
83. Matsumori A, Ono K, Nishio R, et al. Amiodarone inhibits production of tumor necrosis factor-α by human mononuclear cells. A possible mechanism for its effect in heart failure. Circulation 1997;96:1386-9.
84. Matsumori A, Ono K, Nishio R, et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 1997;96:1501-6.
85. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-31.
86. Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor α inhibitory activity. Mol Med 1996;2:506-15.
87. Torre-Amione G, Stetson SJ, Youker KA, et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 1999;100:1189-93.
88. Li YY, Feng Y, McTiernan CF, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001;104:1147-52.
89. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
90. Deswal A, Seta Y, Blosch CM, et al. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNPR:Fc) in patients with advanced heart failure [abstract]. Circulation 1998;96:1323.
91. Bozkurt B, Torre-Amione G, Soran O, et al. Results of a multidose phase I trial with tumor necrosis factor receptor (p75) fusion protein (Etanercept) in patients with heart failure [abstract]. J Am Coll Cardio 1999;184A-5A.
92. Li YY, Kadokami T, McTiernan CF, et al. MMP inhibition modulates TNF-α transgenic mouse phenotype early in the development of heart failure. Am J Physiol Heart Circ Physiol 2002;282:H983-9.
93. Ladenson PW, Sherman SI, Baughman KL, et al, Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci USA 1992;82:5251-5.
94. Stuber F, Petersen M, Bokelmann F, et al. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-α concentrations and outcome of patients with severe sepsis. Crit Care Med 1996;24:381-4.
95. Wilson AG, Symons JA, McDowell TL, et al. Effects of a tumor necrosis factor (TNFα)promoter base transition on transcriptional activity. Br J Rheumatol 1994;33:89.
96. Kaijzel EL, van Krugten MV, Brinkman BM, et al. Functional analysis of a human tumor necrosis factor α (TNF-α) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 1998;4:724-33.
97. Wilson AG, di Giovine FS, Duff GW. Genetics of tumor necrosis factor-α in autoimmune, infectious, and neoplastic diseases. J Inflamm 1995;45:1-12.
98. Wilson AG, di Giovine FS, Blakemore AIF, et al. Single base polymorphism in the human tumor necrosis factor alpha (TNFα) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992;1:353.
99. Danis VA, Millington M, Hyland V, et al. Increased frequency of the uncommon allele of a tumor necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1994;12:127-33.
100. Kubota T, McNamara DM, Wang JJ, et al. Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. Circulation 1998;97:2499-501.
101. Feldman AM, McNamara DM, Wagner DR. AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression. Circulation 1998;99:1397-9.
102. Kadokami T, McTiernan CF, Frye CS, et al. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 2000;106:589-97.
103. Kadokami T, McTiernan CF, Kubota T, et al. Long term estradiol treatment improves survival in male mice with heart failure induced by cardiac specific TNF-expression [abstract]. Circulation 102, II-72
104. Reis SE, Holubkov R, Young JB, et al. Estrogen is associated with improved survival in women with congestive heart failure: analysis of the Vesnarinone Studies. J Am Coll Cardiol 2000;36:529-33.
105. O'Dell JR. TNF-alpha inhibition: the need for a tumor necrosis factor thermostat. Mayo Clin Proc 2001;76:573-5.
106. Campbell IK, O'Donnell K, Lawlor KE, et al. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 2001;107:1519-27.